Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

Inclusion Criteria:

• Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 (Screening).
• Ability to follow study instructions, complete study assessment tools with minimalassistance and no alteration to the assessment tools, and likely to complete allrequired visits.
• Participant meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for schizophrenia as determined by Structured Clinical Interview forDSM-5 (SCID-5).
• Positive and Negative Syndrome Scale (PANSS) total score >= 70 and <= 120 at Visit 1and Visit 2 (Day 1).
• Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positivesymptoms; P1: delusions; P2: conceptual disorganization; P3: hallucinatory behaviour;P6: suspiciousness/persecution at Visit 1 and Visit 2.

Exclusion Criteria:

• Currently meeting DSM-5 criteria for any of the following:
• Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders
• Bipolar I and II disorder
• Autism spectrum disorder, intellectual development disorder, delirium, major/minorneurocognitive disorder
• History of meeting DSM-5 criteria for substance-related disorders (excludingcaffeine-related and tobacco-related disorders) within the prior 3 months before Visit

• Prior participation in any clinical trials involving experimental or investigationaldrugs within 6 months before Visit 1 or planned during the study.
• Female Participants who are pregnant, planning to become pregnant during the course ofthe study, or are currently lactating.